Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.

5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.

Persistent ED in Propecia users is not due to abnormal blood flow.

Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.

Combination therapy is more effective for prostate volumes over 60 ml.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

Post-Finasteride Syndrome causes lasting sexual, mood, and metabolic issues, needing personalized treatment and better informed consent.

5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.

Dutasteride is more effective than finasteride for treating BPH without extra safety risks.

5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.

The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.

New hybrid compound found to effectively prevent hair loss.

Finasteride increases CD8+ T cells in BPH tissues.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

A new combination of tadalafil and finasteride improves drug performance and stability.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.